期刊
ACTA NEUROLOGICA SCANDINAVICA
卷 144, 期 5, 页码 600-607出版社
WILEY
DOI: 10.1111/ane.13504
关键词
anticonvulsants; drugs; epilepsy; generic; physicians; surveys and questionnaires
资金
- Region Skane
- Stig Ragna Gorthon Foundation
- Thelma Zoega Foundation
This study investigated the attitudes of neurologists and neurology residents in Sweden towards generic substitution of antiseizure drugs, revealing that most physicians are in favor of using generic compounds to cut costs and start new treatments, with patient preference being the most crucial factor in decision-making.
Objectives The safety of generic substitution of antiseizure drugs (ASDs) has been questioned for many years. This study aimed to identify physicians' attitudes to the generic substitution of ASDs in epilepsy and which factors were of significance when deciding on compound substitutions. Material and Methods A cross-sectional web-based survey was sent to neurologists and neurology residents in public health care and at private practices in two Swedish regions between February and March 2020. The 30-item survey covered drug- and patient-related factors, as well as considerations relating to practical, cost-related, and pharmacokinetic issues. Results The total response rate was 55.8%. Respondents were generally positive to cutting costs through generic ASD utilization (74%) and prescribing generic compounds when starting a new ASD treatment (84.9%). The most substantial concern was a deterioration in seizure control (17.1%). Physicians refrained from switching if the patient wished to remain on the original compound (76.1%), had a cognitive impairment (52.5%), was on a drug with a narrow therapeutic index (47%), or had shown prior susceptibility to adverse effects (45.6%). Opinions on substitution decisions differed significantly between the Stockholm and Skane regions. Less than one-third of the respondents were aware of supporting guidelines. Conclusions Neurologists generally accept the use of generic antiseizure compounds. Patient preference to remain on brand-name drug treatment was the most important factor that led to avoiding a switch. Our results may constitute material for consensus discussions to decide on quality indicators of interest for future research on substitution outcomes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据